Author:
Zheng Fengxin,Mai Suiqing,Cen Xiaolin,Zhao Pei,Ye Wenjie,Ke Jiale,Lin Shiqin,Hu Huazhong,Guo Zitao,Zhang Shuqin,Liao Hui,Wu Ting,Tian Yuanxin,Zhang Qun,Pang Jianxin,Zhao Zean
Reference39 articles.
1. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet 2021, 397(10287): 1843-1855.
2. Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease;Ponticelli;KidneyInt,2020
3. Safety and tolerability of available urate-lowering drugs: a critical review;Strilchuk;Expert Opin Drug Saf,2019
4. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial;Mackenzie;Lancet,2020
5. Xanthine oxidase inhibitors: patent landscape and clinical development (2015–2020);Singh;Expert Opin Ther Pat,2020